YuLi Biotechnology

YuLi Biotechnology is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of innovative gene therapies for rare diseases. The company leverages its proprietary adeno-associated virus (AAV) vector platform to create treatments for lysosomal storage disorders, including Pompe disease and Fabry disease. Its lead candidate, YL201, is an AAV-mediated gene therapy designed to provide long-term expression of the GAA enzyme and is currently in Phase 1/2 clinical trials. YuLi is backed by prominent investors such as Lilly Asia Ventures and Qiming Venture Partners. The company aims to address significant unmet medical needs in the rare disease space through advanced genetic engineering and optimized vector delivery. YuLi maintains its own GMP manufacturing capabilities to support its clinical pipeline development.